Does antiarrhythmic therapy prevent the development of atrial fibrillation in patients with hypertrophic cardiomyopathy?
Clinical parameters can identify HCM patients at risk for AF, which carries a poor prognosis and is not prevented by long-term antiarrhythmic therapy.
This study shows that patients with HCM who are at risk of AF development can be identified using readily available clinical parameters. The development of AF is associated with a poor prognosis but there was no evidence that antiarrhythmic therapy prevents AF in the long term.
Guttmann et al. (Fri,) studied this question.